A Study Comparing The Impact Of Two Induction Agents Thymoglobulin (rATG) And Alemtuzumab (Campath) On Outcomes In Kidney Transplant Receipients Who Received A Transplant From Deceased Donors With Acute Kidney Injury And Prolonged Cold Ischemia Time (CIT)

Trial Profile

A Study Comparing The Impact Of Two Induction Agents Thymoglobulin (rATG) And Alemtuzumab (Campath) On Outcomes In Kidney Transplant Receipients Who Received A Transplant From Deceased Donors With Acute Kidney Injury And Prolonged Cold Ischemia Time (CIT)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2017 New trial record
    • 03 May 2017 Results presented at the 2017 American Transplant Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top